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Hansen, Pernille B., and Jurgen Schnermann. Vasoconstrictor
and vasodilator effects of adenosine in the kidney. Am J Physiol Renal
Physiol 285: F590–F599, 2003; 10.1152/ajprenal.00051.2003.—Adeno-
sine is an ATP breakdown product that in most vessels causes vasodila-
tation and that contributes to the metabolic control of organ perfusion,
i.e., to the match between oxygen demand and oxygen delivery. In the
renal vasculature, in contrast, adenosine can produce vasoconstriction, a
response that has been suggested to be an organ-specific version of
metabolic control designed to restrict organ perfusion when transport
work increases. However, the vasoconstriction elicited by an intravenous
infusion of adenosine is only short lasting, being replaced within 1–2 min
by vasodilatation. It appears that the steady-state response to the in-
crease of plasma adenosine levels above normal resulting from the
infusion is global renal vasorelaxation that is the result of A2AR activa-
tion in most parts of the renal vasculature, including larger renal
arteries, juxtamedullary afferent arterioles, efferent arterioles, and med-
ullary vessels. A2AR-mediated vasorelaxation is probably facilitated by
endothelial receptors that cause the release of nitric oxide and other
endothelial relaxing factors. In contrast, isolated perfused afferent arte-
rioles of superficial and midcortical nephrons of rabbit and mouse,
especially in their most distal segment at the entrance to the glomerulus,
respond to adenosine with persistent vasoconstriction, indicating pre-
dominant or exclusive expression of A1AR. A1AR in afferent arterioles
are selectively activated from the interstitial aspect of the vessel. This
property can dissociate A1AR activation from changes in vascular
adenosine concentration, a characteristic that is ideally suited for the
role of renal adenosine as a paracrine factor in the control of glomerular
function.
adenosine receptors; vascular resistance; renal blood flow; endothelium
THE EXTRACELLULAR ACTIONS of adenosine are mediated
by binding of the nucleoside to four types of G protein-
coupled membrane receptors, A1, A2a, A2b, and A3
adenosine receptors (A1AR, A2aAR, A2bAR, A3AR). The
expression pattern of adenosine receptor subtypes
throughout the organism is extremely widespread,
commensurate with the organismwide actions of the
nucleoside. In most blood vessels, adenosine elicits
marked vasodilatation, and this effect is mediated by
A2aAR and A2bAR, G protein-coupled receptors that
induce relaxation through the Gs and protein kinase
A pathway. Adenosine-induced vasodilatation reflects
dominance of A2AR in the vasculature of most tissues
and organs. In contrast, A1AR coupled to Gi and PLC
activate motor activity of smooth muscle cells in a
number of muscular tissues (4, 44, 65, 67), but this
receptor subtype is not widely expressed in the vascu-
lature. A1AR are, however, present in blood vessels of
the kidney besides A2AR, and this has made the renal
vascular actions of adenosine comparatively complex.
Evidence obtained in the 1960s solidified an earlier
observation that the kidney vasculature differs from
other vascular beds in that the overall effect of exoge-
nous adenosine may be vasoconstriction (17, 24, 81).
This remarkable observation of a constrictor effect
exerted by a prototypical metabolic dilator has been
the focus of numerous discussions, but its understand-
ing is still incomplete. A renewed interest in the vaso-
constrictor action of adenosine has resulted from the
recent evidence in support of the notion that the nu-
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cleoside is responsible for the afferent arteriolar con-
striction caused by increasing NaCl concentration at
the macula densa, the so-called tubuloglomerular feed-
back (TGF) response (10, 76, 80). Although the vaso-
constrictor potential of adenosine at the organ level has
been the origin of the proposal of adenosine acting as
the constrictor mediator of the TGF response (55), this
reasoning has always been weakened by an apparent,
but not fully acknowledged, internal inconsistency.
The main problem has been that the vasoconstriction
and the accompanying decrease in renal blood flow at
the organ level are only a transient phenomenon,
whereas the steady-state effect of adenosine is either
no change or an increase in renal blood flow (23, 52, 54,
74, 77). Thus the temporal characteristics of the effects
of changes in adenosine levels on global renal vasocon-
striction and on TGF-induced vasoconstriction are ap-
parently entirely different, making it difficult to accept
that these responses are mediated by the same recep-
tors (51). Because the kidney vasculature is sufficiently
heterogeneous, it has been common to argue that aden-
osine causes vasoconstriction in one part of the renal
vascular bed and vasodilatation in another, for exam-
ple, that afferent arteriolar vasoconstriction is accom-
panied and overcome by efferent vasodilatation (77) or
that superficial vasoconstriction is accompanied and
overcome by juxtamedullary vasodilatation (58).
In the present review, we make an attempt to recon-
cile the failure of adenosine to cause a lasting global
renal vasoconstriction with its ability to markedly and
persistently elicit vasoconstriction at the arteriolar
level, both pharmacologically and in its presumed
physiological equivalent, the TGF response. Our over-
all conclusion is that the dominant effect of exogenous
adenosine in the whole kidney is vasodilatation, which
like in other vascular beds is a reflection of the wide
distribution of A2AR in the renal vasculature and their
activation by the supranormal adenosine levels result-
ing from the infusion. However, the distal afferent
arteriole at the entrance to the glomerulus constricts to
adenosine over a much wider concentration range than
any other vascular segment, perhaps reflecting pre-
dominant or exclusive expression of A1AR. Because the
region of A1AR-mediated vasoconstriction at high
adenosine concentrations is restricted to a narrow seg-
ment, the effect of A1AR activation on total renal vas-
cular resistance can be overcome when adenosine lev-
els exceed normal concentrations and A2bAR in other
parts of the renal vasculature are fully engaged.
EXPRESSION OF ADENOSINE RECEPTORS IN
THE KIDNEY
The scarcity of reliable antibodies and radiolabeling
probes and the low expression levels have made it
unexpectedly difficult to precisely identify the adeno-
sine receptor subtypes present along the renal vascu-
lature. Global expression in rat renal cortical and med-
ullary tissue has been shown for all four adenosine
receptors at both the mRNA and protein levels (29, 40,
93). Studies in a preglomerular vessel preparation con-
taining arcuate and interlobular arteries as well as
afferent arterioles have identified the presence of A1AR
protein and mRNA, but this approach does not resolve
the expression profile along the longitudinal axis of the
preglomerular vasculature (29). By in situ hybridiza-
tion, cortical A1AR mRNA was found exclusively at the
glomerular vascular pole but not over the glomerulus
itself (83). Although it is unclear whether the signal
originated in granular, extraglomerular mesangial, or
vascular smooth muscle cells, one may conclude that
some cells at the glomerular vascular pole express
A1AR at much higher levels than any other vessel.
RT-PCR assessment of A1AR mRNA expression has
confirmed its presence in dissected glomeruli (88).
More recently, immunohistochemical evidence has
suggested the presence of A1AR expression in glomer-
ular vessels, presumably in afferent arterioles, and
inside the glomerulum, presumably in mesangial cells
(71). However, of two antibodies directed against dif-
ferent epitopes, only one showed positive staining, an
observation that cautions against overinterpretation of
antibody-based evidence. In regard to A2 receptors, it
has been reported that preglomerular vessels express
only the low-affinity A2bAR at high levels but not the
high-affinity A2aAR receptor protein (29). In situ hy-
bridization failed to detect either A2aAR or A2bAR
mRNA in the renal cortex (83). The profile of adenosine
receptor expression in efferent arterioles has not been
determined with any degree of certainty. In outer med-
ullary descending vasa recta, RT-PCR analysis re-
vealed expression of A1AR, A2aAR, and A2bAR, which
was verified by Southern blotting (33). Receptor-bind-
ing studies using the well-defined panel of stable and
selective ligands for adenosine receptor subtypes have
not been performed in renal vascular tissue. In conclu-
sion, the functional clues that can be derived from
expression studies are relatively limited, but it seems
clear that A1AR are predominantly expressed in affer-
ent arterioles. A2AR, mostly A2bAR, are present in all
preglomerular vessels and in descending vasa recta.
No reliable information is available for efferent arte-
rioles.
ADENOSINE-INDUCED RENAL VASOCONSTRICTION
Effect of Adenosine at the Organ Level
There is abundant evidence to show that bolus injec-
tions of adenosine cause an immediate reduction in
renal blood flow reflecting the response to activation of
high-affinity A1AR (24, 56, 77, 81). Because this blood
flow response was seen when adenosine was injected in
the renal artery, it is not mediated by systemic conse-
quences of adenosine such as a reduction in blood
pressure (24, 54). A reduction in renal blood flow was
also observed during continuous administration of
adenosine, but this decrease was only short lasting and
waned within 1–2 min. The transient constrictor effect
was blocked by nonspecific and A1AR-specific antago-
nists, and it is absent in A1AR knockout mice, indicat-
ing that it is mediated by activation of A1AR (3, 54).
This is supported by the persistent reduction in renal
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blood flow and glomerular filtration rate (GFR) induced
by the infusion of the A1AR-specific agonist cyclohexy-
ladenosine (CHA; see Ref. 13). In the isolated perfused
kidney, CHA causes increasing vasoconstriction in the
dose range between 109 and 107 M, whereas concen-
trations 106 M cause vasodilatation no doubt be-
cause of spillover onto A2AR with undefined vascular
localization (43, 46). On the basis of hemodynamic
modeling, the reduction in renal blood flow was attrib-
uted to a preglomerular, presumably afferent, arterio-
lar vasoconstriction (43, 77). The administration of
A1AR antagonists does not usually cause major in-
creases in renal blood flow, suggesting either that
A1AR activation does not contribute to renal vascular
resistance under resting conditions or that the effect of
the inhibitors is incomplete (3, 34). GFR, on the other
hand, is typically increased by A1AR antagonists (5,
41, 86).
Effect of Adenosine in Glomerular Arterioles
Superficial afferent arterioles. Micropuncture studies
in dogs have shown that an intrarenal adenosine infu-
sion caused a doubling of preglomerular arteriolar re-
sistance (58). In rats, adenosine caused a fall in glo-
merular capillary and welling point pressures and a
fall in superficial nephron GFR (SNGFR), results con-
sistent with preglomerular arteriolar vasoconstriction
(22). In contrast to the transient reduction in renal
blood flow, the effects of adenosine on SNGFR were
persistent. Thus the constrictor response in superficial
nephrons occurs in the absence of changes in renal
plasma flow and with only small or no changes in
kidney GFR (57, 58). These observations appear to be
internally inconsistent, but it is possible that there is
an unusual overrepresentation of A1AR in afferent
arterioles of the very superficial nephron population.
Concordant with a tonic constrictor effect of adenosine
in these nephrons are observations showing that inhi-
bition of A1AR with 1,3-dipropyl-8-cyclopentylxanthine
(DPCPX) or CVT-124 caused afferent arteriolar vaso-
dilatation and an increase in both SNGFR and kidney
GFR (5, 41, 86).
The effect of adenosine on arteriolar tone has been
studied more directly in preparations that permit vi-
sualization of vessel diameters and that are not re-
stricted to a selected population of vessels. Further-
more, in these in vitro preparations, the testable aden-
osine concentrations include the subnormal range,
thereby facilitating the detection of A1AR-mediated
effects. In afferent arterioles of neonatal hamster kid-
neys transplanted in the cheek pouch of adult animals,
adenosine, topically applied through micropipettes,
caused dose-dependent vasoconstriction of afferent ar-
terioles, whereas it dilated the arterioles of the cheek
pouch itself (30). In isolated perfused afferent arte-
rioles from the rabbit, addition of adenosine to the bath
caused vasoconstriction in a dose-dependent fashion
(84). Effects consisted of a 30% reduction in vessel
diameter in proximal parts of the arteriole with maxi-
mum effects being reached at 106 M and smaller
effects at higher concentrations, indicating that in this
part of the arteriole A1AR-mediated vasoconstriction is
partially counteracted by A2bAR-dependent vasodilata-
tion as adenosine concentrations increase. It is consis-
tent with this interpretation that the vasoconstriction
caused by the A1AR agonist CHA was slightly greater
than that caused by adenosine and that it increased
over the entire concentration range from 109 to 104
M (84). However, in the afferent arteriole in the imme-
diate vicinity of the glomerulus, adenosine caused a
monotonic vasoconstriction consisting of a 45% reduc-
tion in vessel diameter at 104 M, the highest concen-
tration tested (Fig. 1). The absence of a discernible
vasodilator effect at concentrations at which A2bAR
should be activated indicates that the short section of
the afferent arteriole close to and inside the glomerulus
is unique in that A1AR-induced constriction does not
appear to be opposed by A2AR to a detectable extent.
Recent experiments in isolated afferent arterioles from
the mouse indicate a similar effectiveness of abluminal
adenosine to vasoconstrict the vessel, particularly at
Fig. 1. Photomicrograph showing the effect of adenosine (Ado; 108
M) on the diameter of a perfused afferent arteriole from rabbit
kidney. Note that there is a marked reduction in the luminal diam-
eter of the arteriole at a narrow region at the entrance of the vessel
into the glomerulus, just before the first branching of the arteriole,
and that the region of highest sensitivity to adenosine is close to the
macula densa (MD) cell plaque. This region showed vasoconstriction
up to a concentration of 104 M adenosine. In contrast, the arteriole
further upstream did not show measurable constriction at the 108
M concentration. Because of specimen positioning, this segment of
high sensitivity is not visible in most preparations. Photograph
taken by H. Weihprecht (84). Black bars define inner vascular
diameters at indicated locations.
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its glomerular entrance segment. The origin of the
arterioles used in both the rabbit and mouse studies
was the midcortical and outer cortical region, so that
arterioles from true juxtamedullary nephrons were not
included. Our results are apparently different from the
net vasodilator effect of CHA in the isolated perfused
kidney that was seen at perfusate concentrations of
105 M and higher (43, 46). Thus the A2AR activated
by high CHA concentrations and determining total
renal vascular resistance in the whole kidney are lo-
calized on vascular segments other than afferent arte-
rioles.
In the hydronephrotic kidney preparation, another
technique permitting direct observation of arteriolar
responses, the effect of adenosine appears to be tran-
sient. With topical application, adenosine caused a
dose-dependent vasoconstriction over the 106 to 104
M dose range that faded within 1–2 min, and a similar
effect was seen in an in vitro perfused hydronephrotic
kidney with luminal application (20, 78). There was no
noticeable steady-state effect of adenosine in the affer-
ent arterioles, whereas interlobular arteries and effer-
ent arterioles showed steady-state vasodilatation at a
concentration of 105 M (20). The abluminal adminis-
tration of CHA, in contrast, had effects comparable to
those found in isolated vessels. These effects consisted
of a stable diameter reduction that was dose dependent
in the range between 108 and 106 M and that was
most pronounced in the distal part of the arteriole
where it caused a maximum effect of about 50%. The
reduction in vascular diameter was accompanied by a
reduction in glomerular blood flow by 30–40% at 107
M and by 50% at 105 M (15, 27). Although NECA
vasodilated all preglomerular vascular segments up to
the arcuate arteries, it caused no change or even a
small constriction in the distal afferent arteriole (16,
27). Although NECA is not a specific A2 agonist, this
finding provides additional support for the notion that
the distal afferent arteriole is unique in its predomi-
nant expression of A1AR. In view of the normal actions
of CHA, the waning effect of adenosine in this prepa-
ration may reflect an increased expression of dilatory
A2AR. It is also of note that at least in the in situ
hydronephrotic kidney model the starting level for the
adenosine addition studies are the prevailing tissue
and plasma adenosine levels, not an adenosine-free
condition.
Juxtamedullary afferent arterioles. Studies of the
effect of adenosine in juxtamedullary arterioles are
important in view of the notion that medullary blood
flow may be regulated by adenosine in a way that is
opposite to cortical blood flow regulation. Juxtamedul-
lary afferent arterioles, studied in a blood-perfused
preparation, respond to abluminal application of aden-
osine at 106 and 105 M with a marked transient and
a smaller steady-state reduction of vessel diameter
that was prevented by the A1AR antagonist KW-3902
and magnified by A2aAR inhibition (11, 28, 47). At
concentrations 105 M, the effect of adenosine was
vasodilatation of juxtamedullary afferent arterioles
that was partially inhibited by the A2aAR antagonist
KF-19837 (47). Diameter evaluations in these studies
were made at a distance of 100 m from the glomerulus
and did not distinguish between proximal and distal
regions of afferent arterioles. Although the steady-
state effect of adenosine in these studies was relatively
small, it may be relevant to point out that a 10%
reduction in vessel diameter translates into a 50%
increase in vessel resistance.
The response of afferent arterioles of juxtamedullary
nephrons to CHA in the hydronephrotic kidney prepa-
ration consisted of a dose-dependent diameter reduc-
tion in the tested concentration range of 108 to 106 M
that was about one-half that seen in more superficial
arterioles (16). Concomitantly, glomerular blood flow
was reduced by 40% at 106 M, a response that was
smaller than seen in superficial nephrons. In contrast
to superficial arterioles, NECA had a small dilator
effect in juxtamedullary afferent arterioles. These
studies indicate that afferent arterioles of juxta-
medullary nephrons may be less responsive to aden-
osine than arterioles from superficial or midcortical
nephrons but that they respond qualitatively similar.
Based on the functional information furnished by CHA
and NECA, one would conclude that afferent arterioles
of juxtamedullary nephrons have a lower expression
level of functional A1AR and a higher level of A2AR
compared with superficial arterioles (16). Neverthe-
less, the dilator action of A1AR inhibition indicates
that, in juxtamedullary afferent arterioles, the domi-
nant effect of adenosine up to a concentration of 10 M
is vasoconstriction.
It is unclear to what extent a loss of A1AR-mediated
constrictor efficiency is responsible for the fleeting re-
duction in total renal blood flow caused by systemic
adenosine, but the following aspects seem pertinent.
The maintenance of constriction in afferent arterioles
for extended periods of time noted in the observational
studies indicates that A1AR in afferent arterioles do
not undergo rapid desensitization, the waning of a
functional response during prolonged or repeated ex-
posure of a receptor to its ligand (27, 30, 47). Most
notably, in recent experiments in isolated afferent ar-
terioles from the mouse, vasoconstriction caused by
adenosine was observed to last for up to 30 min (Han-
sen PB, unpublished observations). The persistent na-
ture of the A1AR-induced vasoconstriction of afferent
arterioles is consonant with the evidence from a num-
ber of studies indicating that the desensitization of
native A1AR in response to prolonged exposure to an
agonist occurs in a time frame of hours to days (60).
Furthermore, the inhibition of forskolin-stimulated ad-
enylate cyclase activity in CHO cells expressing the
human recombinant A1AR was unaffected by a 30-min
treatment with an A1AR agonist (59). We consider it
unlikely that the propensity of A1AR to desensitize
varies between different preparations and between
A1AR expressed in different segments of the renal
vasculature.
Because the adenosine effects in vivo are assessed in
a more complex environment than those encountered
in vitro, it is possible that differences in the presence of
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some modulating factor account for the apparent dif-
ference in the constrictor potential of adenosine seen in
vivo and in vitro. The most intensely studied modula-
tor of A1AR-mediated constrictor actions is ANG II.
There is abundant evidence to show that a reduction in
ambient ANG II levels and the prevention of ANG II
formation and action cause a marked attenuation of
the vasoconstrictor response of the intact kidney to
adenosine (15, 23, 56, 73, 85). Conversely, an elevation
of ambient ANG II concentrations enhances the con-
strictor effect of A1AR activation by adenosine or
A1AR-specific ligands (56, 85). Nevertheless, it is not
clear that differences in ambient ANG II levels can
explain the different responses of intact kidneys and
isolated preparations. One would expect ambient ANG
II concentrations to be lower in the artificial environ-
ment, and adenosine responses should therefore be
blunted, the opposite of what is actually observed. The
possibility that A1AR-mediated vasoconstriction is de-
pendent on the state of arteriolar innervation is not
supported by studies showing an unaltered constrictor
response to an A1AR agonist in denervated compared
with innervated kidneys (61). These results do not lend
support to the possibility that the absence of nervous
input in the isolated preparations importantly modifies
their adenosine response.
Because the studies examining the effect of adeno-
sine on renal blood flow in the whole kidney have been
performed during systemic administration of adeno-
sine, whereas the in vitro experiments were typically
done during abluminal adenosine application, the pos-
sibility exists that the strength of the constrictor re-
sponse varies with the route of administration. In
support of a sidedness in the vascular actions of aden-
osine, we recently observed using laser-Doppler flow-
metry in mice that adenosine given intravenously
caused an increase in superficial renal blood flow,
whereas the infusion of adenosine in the interstitial
region below the flow probe caused a reduction in blood
flow (Hashimoto S, unpublished observations). Fur-
thermore, the vasoconstriction of isolated perfused af-
ferent arterioles from the mouse caused by the bath
addition of adenosine was not seen when adenosine
was added to the luminal perfusate (Hansen PB, un-
published observations). In a study comparing the ef-
fects of intravenous infusion of high- and low-molecu-
lar-weight polyadenylic acids on renal blood flow in
dogs, it has been noted that the low-molecular-weight
compound (mol wt 5,000) caused transient vasocon-
striction like adenosine, whereas the high-molecular-
weight compound (mol wt 100,000) caused an exclusive
and long-lasting vasodilator response that was inhib-
ited by theophylline (79). The authors concluded that
adenosine causes A2AR-mediated vasodilatation through
an intravascular site, whereas the A1AR causing vaso-
constriction are normally accessed from the interstitial
aspect of the vessel. The causes for this sidedness of the
effect of adenosine need to be explored further. It is
conceivable, although unproven, that A1AR are present
in endothelial cells along the renal vasculature and
that adenosine causes the release of nitric oxide (NO)
and perhaps other endothelial vasodilators when ad-
ministered from the vascular but not from the intersti-
tial aspect of the vessel. The resulting A1AR-induced
constriction would therefore be blunted by endothelial
factors only when adenosine is given intravascularly.
In a study in dogs, the administration of nitric oxide
synthesis (NOS) inhibitors caused a marked augmen-
tation in the constrictor response of renal blood flow to
bolus injections of adenosine while the dilator effect of
the A2 agonist CGS-21680 was unaffected, indicating
that adenosine may cause NOS activation through an
A1AR-mediated mechanism (52). Enhancement of
A1AR agonist induced vasoconstriction by NG-nitro-L-
arginine methyl ester, and a marked left shift of the
dose-response relationship between adenosine concen-
tration and vasoconstrictor response has also been
observed in the rat (7, 63). Studies showing a similar
left shift in the adenosine dose-response curve during
application of indomethacin suggest that a vasodilator
prostaglandin may be another endothelial factor op-
posing A1AR-mediated constriction (62). The results of
these studies do not establish that A1AR activation is
directly coupled to the release of NO or prostaglandins
since they are also compatible with the possibility that
the constrictor effect of adenosine is merely enhanced
by the removal of a constitutive vasodilator influence.
It is also of note that adenosine administered in the
vascular space must cross the endothelial cell layer to
interact with smooth muscle cells. In addition to being
a potential physical barrier to the movement of aden-
osine, endothelial cells from coronary blood vessels
have been shown to rapidly metabolize adenosine with
incorporation into various nucleotide pools (45). These
authors suggest that, in coronary vessels, transvascu-
lar adenosine movement may be impeded more by this
metabolic barrier function of the endothelium than by
its physical properties. If the endothelium restricts the
movement of adenosine, one would expect differences
in receptor accessibility dependent on the route of
administration.
In summary, adenosine administered from the ves-
sel outside causes a marked, nontransient vasocon-
striction in afferent arterioles from all regions of the
kidney, although vessels of superficial nephrons ap-
pear to be more sensitive than arterioles of juxtamed-
ullary nephrons. In the afferent arteriole at the glo-
merular entrance, the diameter reduction is monoton-
ically dose dependent, indicating the absence of
adenosine receptors opposing vasoconstriction. In the
more proximal part of the arteriole, the vasoconstrictor
effect of adenosine is blunted (at lower concentrations
by A2aAR and at higher concentrations by A2bAR), but
net vasodilatation does not occur. In the hydrone-
phrotic kidney preparation, the adenosine-induced va-
soconstriction is transient, an effect that may reflect
changes in the vascular response pattern resulting
from chronic elimination of the tubular epithelium. For
reasons that are not entirely clear, A1AR activation
appears to cause a more pronounced constriction of
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afferent arterioles when added to the interstitial as-
pect of the vessel.
ADENOSINE AND RENAL VASODILATATION
Effect of Adenosine at the Organ Level
In contrast to bolus injections, adenosine adminis-
tered by constant infusion is associated with an un-
changed or usually even increased renal blood flow (23,
54, 58, 77). The causes for the steady-state vasodilata-
tion have been ascribed to preferential relaxation of
the efferent arteriolar or medullary vascular beds, but
a convincing argument for either explanation cannot
be made on the basis of studies at the organ level.
Nevertheless, the selective A2AR agonist CGS-21680A
elicits a monophasic reduction in renal vascular resis-
tance, clearly indicating that activation of A2AR is the
cause for the transient nature of the renal constrictor
response to adenosine (35). Furthermore, vasodilata-
tion was seen in isolated perfused kidneys with the
somewhat A2AR-specific agonist NECA (43, 46). It is
noteworthy that GFR is typically suppressed by aden-
osine in a more persistent fashion so that a reduction of
filtration fraction is an invariable consequence of pro-
longed adenosine administration.
Even though obvious, it is relevant to point out that
the infusion studies discussed above examine the effect
of an addition of adenosine to the existing endogenous
nucleoside levels and therefore limit the analysis to the
supranormal concentration range. A consideration of
the baseline adenosine concentrations in plasma and
in the renal interstitial fluid may therefore be helpful
to predict the expected changes in receptor engage-
ment with adenosine infusions, taking into account the
known affinity and dissociation constants of the differ-
ent adenosine receptors. Plasma adenosine levels have
been reported to be somewhere between 100 nM and 1
M, i.e., in the 107 to 106 M range (12, 18, 32, 89,
91). Renal interstitial concentrations of adenosine as
determined by microdialysis have been found to be
between 50 and 200 nM in the cortex and between 160
and 210 nM in the medulla (6, 48–50, 70, 92). Thus
these levels are in the same order of magnitude as
plasma concentrations. The classical early analysis of
ligand binding kinetics to the various adenosine recep-
tors has established that A1AR and A2aAR have affin-
ity constants for adenosine in the order of 108 M,
whereas the affinity of A2bAR is much lower, around
105 M (14, 19, 37, 82). Thus, at the prevailing extra-
cellular adenosine concentrations of 107 M, one
would expect A1AR and the high-affinity A2aAR to be
partly occupied, whereas A2bAR are probably not. The
absence of a major effect of nonspecific AR inhibitors
such as theophylline or aminophylline on renal hemo-
dynamics is consistent with the notion that resting
renal vascular tone represents a state of balanced
A1AR and A2aAR activation (9, 54, 64). The increments
in adenosine concentration resulting from the infusion
should mostly be targeted to the A2bAR receptor pool.
For this simple reason, it is perhaps not surprising that
adenosine infusions result in relaxation of all vessels
expressing A2bAR, the majority of the renal vascula-
ture, and therefore cause global renal vasodilatation.
In view of the evidence discussed above that the
afferent arteriole near the glomerulus may not vaso-
dilate even at elevated levels of adenosine, at least
when adenosine is administered from the interstitial
side, it is relevant to point out that the afferent
arteriole is not the only resistance vessel in the
kidney. Aside from the significant contribution of the
efferent arterioles, interlobular arteries in the rat
kidney have been estimated to represent as much as
50% of renal preglomerular resistance (8, 26) and
have also been shown to contribute importantly to
autoregulatory adjustments of renal vascular resis-
tance (25). Furthermore, the renal artery has been
shown to regulate renal vascular resistance by the
release and downstream action of endothelium-
derived vasodilators (31). Therefore, global renal va-
sodilatation may well occur in the absence of overt
vasodilatation in afferent arterioles.
It is now well recognized that the majority of vaso-
dilator agents act by binding to their receptors on
endothelial cells and by eliciting the generation and
release of endothelial relaxing factors, most notably
NO, endothelial hyperpolarizing factor, and prosta-
glandins. The presence of A2AR in endothelial cells of
the renal vasculature has not been established di-
rectly, but a number of studies in various excised
vessel preparations indicate that adenosine-induced
vasodilatation is probably to some extent endothelium
dependent. In the majority of these studies, adenosine
appears to augment NOS activity and NO release
through an A2AR-mediated process, an action that
would enhance the dilator component rather than di-
minish the constrictor component of the adenosine
actions (1, 21, 38, 75, 90). In addition, adenosine has
also been reported to dilate rabbit renal arteries
through an endothelial relaxing factor that does not
appear to be NO (66). Finally, adenosine has been
shown to consistently stimulate the production of NO
in cultured endothelial cells, usually through an A2AR-
dependent mechanism (36, 53, 87). Thus, in addition to
the possible blunting of A1AR-induced vasoconstriction
as discussed above, endothelial dilator factors gener-
ated in response to A2AR activation may enhance renal
vasodilatation, thereby contributing to the waning re-
nal constriction in the kidney during intravenous ad-
ministration.
The overall conclusion from these studies at the
organ level would be that the intravenous administra-
tion of exogenous adenosine, i.e., an elevation of
plasma adenosine concentrations above normal, causes
a short-lasting net vasoconstriction mediated by high-
affinity A1AR. However, this effect is overcome, at the
elevated plasma adenosine levels resulting from the
addition of exogenous nucleoside, by the simultaneous
activation of lower-affinity A2AR so that the dominat-
ing and lasting effect is net vasodilatation in most
cases.
F595INVITED REVIEW
AJP-Renal Physiol • VOL 285 • OCTOBER 2003 • www.ajprenal.org
 by 10.220.33.4 on January 15, 2017
http://ajprenal.physiology.org/
D
ow
nloaded from
 
Effect of Adenosine in Efferent Arterioles
Dilatation of efferent arterioles has been suggested
as one of the reasons for the return of renal blood flow
to normal or supranormal values during an adenosine
infusion, a notion that is mainly based on the observed
reduction in filtration fraction (42, 77). However, it has
been difficult to establish an unequivocal vasodilator
action of adenosine in preparations in which the arte-
riole can be observed directly. In the blood-perfused
juxtamedullary nephron preparation, the effect of
adenosine on the diameter of efferent arterioles was
qualitatively similar to that seen in afferent arterioles
consisting of a stable diameter reduction by 6% at a
concentration of 105 M, a constrictor effect that was
smaller than that seen in afferent arterioles (11, 47).
Vasodilatation in the presence of an A1AR blocker, and
enhanced constriction in the presence of an A2aAR
blocker, resembled the effects noted in afferent arte-
rioles. On the other hand, in the hydronephrotic kid-
ney, adenosine at 105 M caused a steady-state diam-
eter increase of 14% that was not changed much by
the A1AR antagonist DPCPX but was abolished by the
A2AR antagonist 3,7-dimethyl-L-propargylxanthine
(20). These results suggest the absence of A1AR in
efferent arterioles in this preparation, a notion sup-
ported by previous reports using the same preparation
in which the A1AR agonist CHA caused only small or
no diameter reductions in efferent arterioles up to a
concentration of 105 M (16, 27). In contrast, NECA
induced a small efferent vasodilatation and an increase
in glomerular blood flow (27). Thus adenosine effects in
the efferent arteriole are not very pronounced and
appear to consist of small constrictions at lower and
small dilations at higher concentrations. The small
magnitude of both constrictor and dilator effects sug-
gests rather low levels of expression for all receptor
subtypes. Overall, we conclude that a dilator effect of
efferent arterioles may contribute to the loss of net
vasoconstriction at elevated adenosine levels but that
it is unlikely to account for the full dilator action of
adenosine.
Adenosine and medullary blood flow. Vasodilatation
of the vessels controlling renal medullary blood flow
has been proposed as being responsible for the net
vasodilatation of the kidney in response to continuous
intravenous infusion of adenosine. Renal blood flow
distribution measured with microspheres showed an
increase in inner cortical blood flow, whereas outer
cortical blood flow was unchanged (72). The magnitude
of this increase varied between 23 and 94%, depending
on the renin status of the dogs. Interstitial infusion of
adenosine induced an increase in medullary blood flow
measured with laser-Doppler flowmetry by 40% (2).
Direct infusion of adenosine in the renal medulla
caused an 25–30% increase in both outer and inner
medullary blood flows (92). Direct assessment of blood
flow in single inner medullary vasa recta by videomi-
croscopy showed an increase in red cell velocity with-
out a diameter change only during intrarenal adeno-
sine infusion at the highest dose tested (39). The in-
fused amounts did not induce significant changes in
inulin or p-aminohippuric acid clearances. In isolated
perfused outer medullary vasa recta, the administra-
tion of increasing concentrations of adenosine induced
a biphasic response, consisting of a vasoconstriction in
the dose range between 1011 and 107 M and a vaso-
dilatation at 106 to 105 M (68). In contrast to cortical
resistance vessels, administration of adenosine to vasa
recta preconstricted by ANG II leads to vasodilatation
(68, 69). The concentration of adenosine in the inter-
stitial fluid of the medulla is between 107 and 106 M,
a level where one may expect not much impact on
resting tone but where an increase of adenosine con-
centration should cause vasodilatation (70, 92). In
summary, most studies agree that the administration
of adenosine causes an increase in medullary blood
flow by relaxing both juxtamedullary afferent and per-
haps efferent arterioles and outer medullary vasa recta
pericytes. Nevertheless, for quantitative reasons, we
consider it unlikely that this increase in medullary
blood flow can be the only reason responsible for the
overall increase in total renal blood flow seen with
constant infusions of adenosine. Medullary blood flow
represents only 10% of total renal blood flow. Thus a
reduction in cortical blood flow by 50% would require a
more than fivefold increase in medullary flow for com-
pensation. The magnitude of the observed increase in
medullary blood flow, variable as it may be, is not even
close to this expectation. Thus much of the compensa-
tory increase in total renal blood flow in response to
continuous adenosine infusions must take place in the
renal cortex.
In conclusion, the intravenous infusion of adenosine,
i.e., an increase of plasma adenosine levels above nor-
mal, causes a renal vasodilator response that is the
result of A2AR-mediated vasorelaxation in most parts
of the renal vasculature, including larger renal arter-
ies, juxtamedullary afferent arterioles, efferent arte-
rioles, and medullary vessels (Fig. 2). A combination of
Fig. 2. Relationship between the concentration of adenosine and the
%decrease in the diameter of afferent arterioles near the glomerulus
(AA-Glom), proximal afferent arterioles (AA), juxtamedullary affer-
ent arterioles (JM-AA), juxtamedullary efferent arterioles (JM-EA),
and outer medullary descending vasa recta (OMDVR). There are no
data for the missing vessels. Diameter decrements are a measure of
vessel resistance. Data are from Refs. 47, 68, and 84.
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these effects, rather than one single action, is respon-
sible for the relaxation caused by exogenous adenosine
in the whole kidney. A2AR-mediated vasorelaxation
may be facilitated by intravascular receptors, most
likely on endothelial cells, causing the release of NO
and other endothelial relaxing factors. In contrast, the
afferent arteriole, especially in the segment closest to
the glomerulus, responds to adenosine with vasocon-
striction over a wide concentration range. Afferent
arteriolar A1AR are selectively activated from the in-
terstitial aspect of the vessel, a characteristic that is
ideally suited for the presumed physiological role of
these receptors, the mediation of the TGF response.
DISCLOSURES
Work from the authors’ laboratory was supported by intramural
funds from the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK). P. B. Hansen was the recipient of a
Visiting Fellowship of the NIDDK.
REFERENCES
1. Abebe W, Hussain T, Olanrewaju H, and Mustafa SJ. Role
of nitric oxide in adenosine receptor-mediated relaxation of por-
cine coronary artery. Am J Physiol Heart Circ Physiol 269:
H1672–H1678, 1995.
2. Agmon Y, Dinour D, and Brezis M. Disparate effects of
adenosine A1- and A2-receptor agonists on intrarenal blood flow.
Am J Physiol Renal Fluid Electrolyte Physiol 265: F802–F806,
1993.
3. Aki Y, Tomohiro A, Nishiyama A, Kiyomoto K, Kimura S,
and Abe Y. Effects of KW-3902, a selective and potent adenosine
A1 receptor antagonist, on renal hemodynamics and urine for-
mation in anesthetized dogs. Pharmacology 55: 193–201, 1997.
4. Ali S, Metzger WJ, and Mustafa SJ. Simultaneous measure-
ment of cyclopentyladenosine-induced contraction and intracel-
lular calcium in bronchial rings from allergic rabbits and it’s
antagonism. J Pharmacol Exp Ther 278: 639–644, 1996.
5. Balakrishnan VS, Coles GA, and Williams JD. A potential
role for endogenous adenosine in control of human glomerular
and tubular function. Am J Physiol Renal Fluid Electrolyte
Physiol 265: F504–F510, 1993.
6. Baranowski RL and Westenfelder C. Estimation of renal
interstitial adenosine and purine metabolites by microdialysis.
Am J Physiol Renal Fluid Electrolyte Physiol 267: F174–F182,
1994.
7. Barrett RJ and Droppleman DA. Interactions of adenosine
A1 receptor-mediated renal vasoconstriction with endogenous
nitric oxide and ANG II. Am J Physiol Renal Fluid Electrolyte
Physiol 265: F651–F659, 1993.
8. Boknam L, Ericson AC, Aberg B, and Ulfendahl HR. Flow
resistance of the interlobular artery in the rat kidney. Acta
Physiol Scand 111: 159–163, 1981.
9. Brater DC, Kaojarern S, and Chennavasin P. Pharmacody-
namics of the diuretic effects of aminophylline and acetazol-
amide alone and combined with furosemide in normal subjects.
J Pharmacol Exp Ther 227: 92–97, 1983.
10. Brown R, Ollerstam A, Johansson B, Skott O, Gebre-Med-
hin S, Fredholm B, and Persson AE. Abolished tubuloglo-
merular feedback and increased plasma renin in adenosine A1
receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol
281: R1362–R1367, 2001.
11. Carmines PK and Inscho EW. Renal arteriolar angiotensin
responses during varied adenosine receptor activation. Hyper-
tension 23: I114–I119, 1994.
12. Chen YF, Li PL, and Zou AP. Effect of hyperhomocysteinemia
on plasma or tissue adenosine levels and renal function. Circu-
lation 106: 1275–1281, 2002.
13. Cook CB and Churchill PC. Effects of renal denervation on
the renal responses of anesthetized rats to cyclohexyladenosine.
Can J Physiol Pharmacol 62: 934–938, 1984.
14. Daly JW, Butts-Lamb P, and Padgett W. Subclasses of aden-
osine receptors in the central nervous system: interaction with
caffeine and related methylxanthines. Cell Mol Neurobiol 3:
69–80, 1983.
15. Dietrich MS, Endlich K, Parekh N, and Steinhausen M.
Interaction between adenosine and angiotensin II in renal mi-
crocirculation. Microvasc Res 41: 275–288, 1991.
16. Dietrich MS and Steinhausen M. Differential reactivity of
cortical and juxtamedullary glomeruli to adenosine-1 and aden-
osine-2 receptor stimulation and angiotensin-converting enzyme
inhibition. Microvasc Res 45: 122–133, 1993.
17. Drury A and Szent-Gyorgy A. The physiological activity of
adenosine compounds with special reference to their action upon
mammalian heart. J Physiol 68: 213–226, 1929.
18. Franco M, Bobadilla NA, Suarez J, Tapia E, Sanchez L,
and Herrera-Acosta J. Participation of adenosine in the renal
hemodynamic abnormalities of hypothyroidism. Am J Physiol
Renal Fluid Electrolyte Physiol 270: F254–F262, 1996.
19. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW,
Harden TK, Jacobson KA, Leff P, and Williams M. Nomen-
clature and classification of purinoceptors. Pharmacol Rev 46:
143–156, 1994.
20. Gabriels G, Endlich K, Rahn KH, Schlatter E, and Stein-
hausen M. In vivo effects of diadenosine polyphosphates on rat
renal microcirculation. Kidney Int 57: 2476–2484, 2000.
21. Grbovic L, Radenkovic M, Prostran M, and Pesic S. Char-
acterization of adenosine action in isolated rat renal artery:
possible role of adenosine A(2A) receptors. Gen Pharmacol 35:
29–36, 2000.
22. Haas JA and Osswald H. Adenosine induced fall in glomerular
capillary pressure: effect of ureteral obstruction and aortic con-
striction in the Munich-Wistar rat kidney. Naunyn Schmiede-
bergs Arch Pharmacol 317: 86–89, 1981.
23. Hall JE, Granger JP, and Hester RL. Interactions between
adenosine and angiotensin II in controlling glomerular filtration.
Am J Physiol Renal Fluid Electrolyte Physiol 248: F340–F346,
1985.
24. Hashimoto K and Kumakura S. The pharmacological features
of the coronary, renal, mesenteric, and femoral arteries. Japn
J Physiol 15: 540–551, 1965.
25. Heyeraas KJ and Aukland K. Interlobular arterial resistance:
influence of renal arterial pressure and angiotensin II. Kidney
Int 31: 1291–1298, 1987.
26. Heyeraas Tonder KJ and Aukland K. Interlobular arterial
pressure in the rat kidney. Renal Physiol 2: 214–221, 1979.
27. Holz FG and Steinhausen M. Renovascular effects of adeno-
sine receptor agonists. Renal Physiol 10: 272–282, 1987.
28. Inscho EW, Ohishi K, and Navar LG. Effects of ATP on pre-
and postglomerular juxtamedullary microvasculature. Am J
Physiol Renal Fluid Electrolyte Physiol 263: F886–F893, 1992.
29. Jackson EK, Zhu C, and Tofovic SP. Expression of adenosine
receptors in the preglomerular microcirculation. Am J Physiol
Renal Physiol 283: F41–F51, 2002.
30. Joyner WL, Mohama RE, Myers TO, and Gilmore JP. The
selective response to adenosine of renal microvessels from ham-
ster explants. Microvasc Res 35: 122–131, 1988.
31. Kon V, Harris RC, and Ichikawa I. A regulatory role for large
vessels in organ circulation. Endothelial cells of the main renal
artery modulate intrarenal hemodynamics in the rat. J Clin
Invest 85: 1728–1733, 1990.
32. Kost CK Jr and Jackson EK. Effect of angiotensin II on
plasma adenosine concentrations in the rat. J Cardiovasc Phar-
macol 17: 838–845, 1991.
33. Kreisberg MS, Silldorff EP, and Pallone TL. Localization of
adenosine-receptor subtype mRNA in rat outer medullary de-
scending vasa recta by RT-PCR. Am J Physiol Heart Circ Physiol
272: H1231–H1238, 1997.
34. Kuan CJ, Herzer WA, and Jackson EK. Cardiovascular and
renal effects of blocking A1 adenosine receptors. J Cardiovasc
Pharmacol 21: 822–828, 1993.
35. Levens N, Beil M, and Schulz R. Intrarenal actions of the new
adenosine agonist CGS 21680A, selective for the A2 receptor.
J Pharmacol Exp Ther 257: 1013–1019, 1991.
F597INVITED REVIEW
AJP-Renal Physiol • VOL 285 • OCTOBER 2003 • www.ajprenal.org
 by 10.220.33.4 on January 15, 2017
http://ajprenal.physiology.org/
D
ow
nloaded from
 
36. Li J, Fenton RA, Wheeler HB, Powell CC, Peyton BD,
Cutler BS, and Dobson JG Jr. Adenosine A2a receptors in-
crease arterial endothelial cell nitric oxide. J Surg Res 80:
357–364, 1998.
37. Londos C, Cooper DM, and Wolff J. Subclasses of external
adenosine receptors. Proc Natl Acad Sci USA 77: 2551–2554,
1980.
38. Martin PL and Potts AA. The endothelium of the rat renal
artery plays an obligatory role in A2 adenosine receptor-medi-
ated relaxation induced by 5-N-ethylcarboxamidoadenosine and
N6-cyclopentyladenosine. J Pharmacol Exp Ther 270: 893–899,
1994.
39. Miyamoto M, Yagil Y, Larson T, Robertson C, and Jamison
RL. Effects of intrarenal adenosine on renal function and med-
ullary blood flow in the rat. Am J Physiol Renal Fluid Electrolyte
Physiol 255: F1230–F1234, 1988.
40. Morton MJ, Sivaprasadarao A, Bowmer CJ, and Yates MS.
Adenosine receptor mRNA levels during postnatal renal matu-
ration in the rat. J Pharm Pharmacol 50: 649–654, 1998.
41. Munger KA and Jackson EK. Effects of selective A1 receptor
blockade on glomerular hemodynamics: involvement of renin-
angiotensin system. Am J Physiol Renal Fluid Electrolyte
Physiol 267: F783–F790, 1994.
42. Murray RD and Churchill PC. Effects of adenosine receptor
agonists in the isolated, perfused rat kidney. Am J Physiol Heart
Circ Physiol 247: H343–H348, 1984.
43. Murray RD and Churchill PC. Concentration dependency of
the renal vascular and renin secretory responses to adenosine
receptor agonists. J Pharmacol Exp Ther 232: 189–193, 1985.
44. Murthy KS, McHenry L, Grider JR, and Makhlouf GM.
Adenosine A1 and A2b receptors coupled to distinct interactive
signaling pathways in intestinal muscle cells. J Pharmacol Exp
Ther 274: 300–306, 1995.
45. Nees S, Herzog V, Becker BF, Bock M, Des Rosiers C, and
Gerlach E. The coronary endothelium: a highly active metabolic
barrier for adenosine. Basic Res Cardiol 80: 515–529, 1985.
46. Nies AS, Beckmann ML, and Gerber JG. Contrasting effects
of changes in salt balance on the renovascular response to
A1-adenosine receptor stimulation in vivo and in vitro in the rat.
J Pharmacol Exp Ther 256: 542–546, 1991.
47. Nishiyama A, Inscho EW, and Navar LG. Interactions of
adenosine A1 and A2a receptors on renal microvascular reactiv-
ity. Am J Physiol Renal Physiol 280: F406–F414, 2001.
48. Nishiyama A, Kimura S, He H, Miura K, Rahman M, Fuji-
sawa Y, Fukui T, and Abe Y. Renal interstitial adenosine
metabolism during ischemia in dogs. Am J Physiol Renal Physiol
280: F231–F238, 2001.
49. Nishiyama A, Miura K, Miyatake A, Fujisawa Y, Yue W,
Fukui T, Kimura S, and Abe Y. Renal interstitial concentra-
tion of adenosine during endotoxin shock. Eur J Pharmacol 385:
209–216, 1999.
50. Nishiyama A, Miyatake A, Aki Y, Fukui T, Rahman M,
Kimura S, and Abe Y. Adenosine A(1) receptor antagonist
KW-3902 prevents hypoxia-induced renal vasoconstriction.
J Pharmacol Exp Ther 291: 988–993, 1999.
51. Nishiyama A and Navar LG. ATP mediates tubuloglomerular
feedback. Am J Physiol Regul Integr Comp Physiol 283: R273–
R279, 2002.
52. Okumura M, Miura K, Yamashita Y, Yukimura T, and
Yamamoto K. Role of endothelium-derived relaxing factor in
the in vivo renal vascular action of adenosine in dogs. J Phar-
macol Exp Ther 260: 1262–1267, 1992.
53. Olanrewaju HA and Mustafa SJ. Adenosine A(2A) and A(2B)
receptors mediated nitric oxide production in coronary artery
endothelial cells. Gen Pharmacol 35: 171–177, 2000.
54. Osswald H. Renal effects of adenosine and their inhibition by
theophylline in dogs. Naunyn Schmiedebergs Arch Pharmacol
288: 79–86, 1975.
55. Osswald H, Nabakowski G, and Hermes H. Adenosine as a
possible mediator of metabolic control of glomerular filtration
rate. Int J Biochem 12: 263–267, 1980.
56. Osswald H, Schmitz HJ, and Heidenreich O. Adenosine
response of the rat kidney after saline loading, sodium restric-
tion and hemorrhagia. Pflu¨gers Arch 357: 323–333, 1975.
57. Osswald H, Schmitz HJ, and Kemper R. Renal action of
adenosine: effect on renin secretion in the rat. Naunyn
Schmiedebergs Arch Pharmacol 303: 95–99, 1978.
58. Osswald H, Spielman WS, and Knox FG. Mechanism of
adenosine-mediated decreases in glomerular filtration rate in
dogs. Circ Res 43: 465–469, 1978.
59. Palmer TM, Benovic JL, and Stiles GL. Molecular basis for
subtype-specific desensitization of inhibitory adenosine recep-
tors: analysis of a chimeric A1-A3 adenosine receptor. J Biol
Chem 271: 15272–15278, 1996.
60. Palmer TM and Stiles GL. Structure-function analysis of in-
hibitory adenosine receptor regulation. Neuropharmacology 36:
1141–1147, 1997.
61. Panzacchi G, Demarchi B, Busca G, Protasoni G, Golin R,
and Stella A. Effects of adenosine receptor agonists on renal
function in anaesthetized rats. J Hypertens 15: 1785–1789, 1997.
62. Pflueger AC, Gross JM, and Knox FG. Adenosine-induced
renal vasoconstriction in diabetes mellitus rats: role of prosta-
glandins. Am J Physiol Regul Integr Comp Physiol 277: R1410–
R1417, 1999.
63. Pflueger AC, Osswald H, and Knox FG. Adenosine-induced
renal vasoconstriction in diabetes mellitus rats: role of nitric
oxide. Am J Physiol Renal Physiol 276: F340–F346, 1999.
64. Premen AJ, Hall JE, Mizelle HL, and Cornell JE. Mainte-
nance of renal autoregulation during infusion of aminophylline
or adenosine. Am J Physiol Renal Fluid Electrolyte Physiol 248:
F366–F373, 1985.
65. Reeves JJ, Jarvis JE, Sheehan MJ, and Strong P. Further
investigations into adenosine A1 receptor-mediated contraction
in rat colonic muscularis mucosae and its augmentation by
certain alkylxanthine antagonists. Br J Pharmacol 114: 999–
1004, 1995.
66. Rump LC, Jabbari TJ, von Kugelgen I, and Oberhauser V.
Adenosine mediates nitric-oxide-independent renal vasodilation
by activation of A2A receptors. J Hypertens 17: 1987–1993, 1999.
67. Shim JO, Shin CY, Lee TS, Yang SJ, An JY, Song HJ, Kim
TH, Huh IH, and Sohn UD. Signal transduction mechanism
via adenosine A1 receptor in the cat esophageal smooth muscle
cells. Cell Signal 14: 365–372, 2002.
68. Silldorff EP, Kreisberg MS, and Pallone TL. Adenosine
modulates vasomotor tone in outer medullary descending vasa
recta of the rat. J Clin Invest 98: 18–23, 1996.
69. Silldorff EP and Pallone TL. Adenosine signaling in outer
medullary descending vasa recta. Am J Physiol Regul Integr
Comp Physiol 280: R854–R861, 2001.
70. Siragy HM and Linden J. Sodium intake markedly alters
renal interstitial fluid adenosine. Hypertension 27: 404–407,
1996.
71. Smith JA, Sivaprasadarao A, Munsey TS, Bowmer CJ, and
Yates MS. Immunolocalisation of adenosine A(1) receptors in
the rat kidney. Biochem Pharmacol 61: 237–244, 2001.
72. Spielman WS, Britton SL, and Fiksen-Olsen MJ. Effect of
adenosine on the distribution of renal blood flow in dogs. Circ Res
46: 449–456, 1980.
73. Spielman WS and Osswald H. Blockade of postocclusive renal
vasoconstriction by an angiotensin II antagonists: evidence for
an angiotensin-adenosine interaction. Am J Physiol Renal Fluid
Electrolyte Physiol 237: F463–F467, 1979.
74. Spielman WS and Thompson CI. A proposed role for adeno-
sine in the regulation of renal hemodynamics and renin release.
Am J Physiol Renal Fluid Electrolyte Physiol 242: F423–F435,
1982.
75. Steinhorn RH, Morin FC III, Van Wylen DG, Gugino SF,
Giese EC, and Russell JA. Endothelium-dependent relax-
ations to adenosine in juvenile rabbit pulmonary arteries and
veins. Am J Physiol Heart Circ Physiol 266: H2001–H2006,
1994.
76. Sun D, Samuelson LC, Yang T, Huang Y, Paliege A, Saun-
ders T, Briggs J, and Schnermann J. Mediation of tubulo-
glomerular feedback by adenosine: evidence from mice lacking
adenosine 1 receptors. Proc Natl Acad Sci USA 98: 9983–9988,
2001.
F598 INVITED REVIEW
AJP-Renal Physiol • VOL 285 • OCTOBER 2003 • www.ajprenal.org
 by 10.220.33.4 on January 15, 2017
http://ajprenal.physiology.org/
D
ow
nloaded from
 
77. Tagawa H and Vander AJ. Effects of adenosine compounds on
renal function and renin secretion in dogs. Circ Res 26: 327–338,
1970.
78. Tang L, Parker M, Fei Q, and Loutzenhiser R. Afferent
arteriolar adenosine A2a receptors are coupled to KATP in in vitro
perfused hydronephrotic rat kidney. Am J Physiol Renal Physiol
277: F926–F933, 1999.
79. Thompson CI and Spielman WS. Renal hemodynamic effects
of exogenously administered adenosine and polyadenylic acid.
Am J Physiol Renal Fluid Electrolyte Physiol 263: F816–F823,
1992.
80. Thomson S, Bao D, Deng A, and Vallon V. Adenosine formed
by 5-nucleotidase mediates tubuloglomerular feedback. J Clin
Invest 106: 289–298, 2000.
81. Thurau K. Renal hemodynamics. Am J Med 36: 850–860, 1964.
82. Van Calker D, Muller M, and Hamprecht B. Adenosine
regulates via two different types of receptors the accumulation of
cyclic AMP in cultured brain cells. J Neurochem 33: 999–1005,
1979.
83. Weaver DR and Reppert SM. Adenosine receptor gene expres-
sion in rat kidney. Am J Physiol Renal Fluid Electrolyte Physiol
263: F991–F995, 1992.
84. Weihprecht H, Lorenz JN, Briggs JP, and Schnermann J.
Vasomotor effects of purinergic agonists in isolated rabbit affer-
ent arterioles. Am J Physiol Renal Fluid Electrolyte Physiol 263:
F1026–F1033, 1992.
85. Weihprecht H, Lorenz JN, Briggs JP, and Schnermann J.
Synergistic effects of angiotensin and adenosine in the renal
microvasculature. Am J Physiol Renal Fluid Electrolyte Physiol
266: F227–F239, 1994.
86. Wilcox CS, Welch WJ, Schreiner GF, and Belardinelli L.
Natriuretic and diuretic actions of a highly selective adenosine
A1 receptor antagonist. J Am Soc Nephrol 10: 714–720, 1999.
87. Wyatt AW, Steinert JR, Wheeler-Jones CP, Morgan AJ,
Sugden D, Pearson JD, Sobrevia L, and Mann GE. Early
activation of the p42/p44MAPK pathway mediates adenosine-
induced nitric oxide production in human endothelial cells: a
novel calcium-insensitive mechanism. FASEB J 16: 1584–1594,
2002.
88. Yamaguchi S, Umemura S, Tamura K, Iwamoto T, Nyui N,
Ishigami T, and Ishii M. Adenosine A1 receptor mRNA in
microdissected rat nephron segments. Hypertension 26: 1181–
1185, 1995.
89. Yoneyama Y, Suzuki S, Sawa R, Otsubo Y, Power GG, and
Araki T. Plasma adenosine levels increase in women with nor-
mal pregnancies. Am J Obstet Gynecol 182: 1200–1203, 2000.
90. Zanzinger J and Bassenge E. Coronary vasodilation to ace-
tylcholine, adenosine and bradykinin in dogs: effects of inhibi-
tion of NO-synthesis and captopril. Eur Heart J 14, Suppl I:
164–168, 1993.
91. Zhang YL, Li T, and Lautt WW. Adenosine metabolism in vivo.
Proc West Pharmacol Soc 37: 15–16, 1994.
92. Zou AP, Nithipatikom K, Li PL, and Cowley AW Jr. Role of
renal medullary adenosine in the control of blood flow and
sodium excretion. Am J Physiol Regul Integr Comp Physiol 276:
R790–R798, 1999.
93. Zou AP, Wu F, Li PL, and Cowley AW Jr. Effect of chronic
salt loading on adenosine metabolism and receptor expression in
renal cortex and medulla in rats. Hypertension 33: 511–516,
1999.
F599INVITED REVIEW
AJP-Renal Physiol • VOL 285 • OCTOBER 2003 • www.ajprenal.org
 by 10.220.33.4 on January 15, 2017
http://ajprenal.physiology.org/
D
ow
nloaded from
 
